Vimarsana
Biggest News Aggregation in the World

Page 22 - Bio Developments News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bio Developments. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bio Developments Today - Breaking & Trending Today

Candel Therapeutics bags FDA fast track for pancreatic cancer drug - Vimarsana News

Candel Therapeutics bags FDA fast track for pancreatic cancer drug

Candel Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its lead adenovirus asset CAN-2409, for the treatment of pancreatic cancer.

SolasCure demonstrates proof-of-concept in trial of new maggot-derived wound gel - Vimarsana News

SolasCure demonstrates proof-of-concept in trial of new maggot-derived wound gel

Biotech company SolasCure has announced the results of its proof-of-concept phase 2 trial investigating its wound gel for chronic venous leg ulcer patients.

BioSenic secures key funding as it pushes for phase 3 trial - Vimarsana News

BioSenic secures key funding as it pushes for phase 3 trial

Biosenic, a company specializing in serious autoimmune and inflammatory diseases and cell therapy, has secured funding from Singapore-based TrialCap, in a bid to accelerate its phase 3 clinical development.

UCL picks ViroCell as partner for childhood cancer treatment - Vimarsana News

UCL picks ViroCell as partner for childhood cancer treatment

ViroCell Biologics, a London-based viral vector CDMO for cell and gene therapy clinical trials, has partnered with University College London (UCL) to advance its pediatric cancer treatment.

Naobios receives $1.87 million to fund human viral challenge agent - Vimarsana News

Naobios receives $1.87 million to fund human viral challenge agent

Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, has received a $1.87 million grant from the Bill & Melinda Gates Foundation to support its vaccine development efforts.